Feasibility study of Pemetrexed/Cisplatin/Bevacizumab and EGFR-TKIs in alternating cycles followed by Pemetrexed/Bevacizumab and EGFR-TKIs in alternating cycles as maintenance therapy for patients with stage IV EGFR mutation positive non-small-cell lung cancer
- Conditions
- Stage IV EGFR mutation positive non-small-cell lung cancer patients
- Registration Number
- JPRN-UMIN000005917
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 21
Not provided
1)Squamous Cell Carcinoma 2)Interstitial pneumonia or pulmonary fibrosis on Chest Xray 3)Superior vena cava syndrome 4)Renal dysfunction 5)Patients with superior vena cava syndrome 6)Central nervous system metastases 7)Other active malignancy 8)Uncontrollable hypertension, uncontrollable diabetes 9)Patients who are diagnosed as cirrhosis with image orclinical examination 10)Heart disease as follows; unstable angina, myocardial infarction within 6 months, post-PTCA or post-CAGB, congestive heart failure, arrhythmia requiring treatment 11)Pregnancy, lactation or no intention to practice birth control 12)Sever drug allergy 13)Acute inflammatory disease 14)No consent to blood transfusion or other supportive care 15)With a clinical bleeding tendency 16)History of sever hemoptysis or bloody sputum 17)Cavity lesion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment completion rate of induction therapy
- Secondary Outcome Measures
Name Time Method Response Rate Disease Controle Rate Pprogression-Free-Survival 1-year Survival Rate Safety Overall Survival